Skip to main content
Clinical Trials/JPRN-UMIN000022048
JPRN-UMIN000022048
Completed
未知

The prospective study to evaluate the efficacy of the combination therapy of inhaled budesonide/formoterol fumarate, clarithromycin, and montelukast in AFO after allogeneic SCT - Chiba AFO-01 study

Department of Hematology, Chiba University Hospital0 sites85 target enrollmentApril 25, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Air flow obstruction after allogeneic SCT
Sponsor
Department of Hematology, Chiba University Hospital
Enrollment
85
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 25, 2016
End Date
June 30, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Hematology, Chiba University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Known history of intolerance or allergy to any triplet component. 2\. The patient who has past history of asthma and had attack within one year. 3\. The patient who has already been treated with the triplet combination. 4\. The patient who has active infection 5\. The patient who has mental disability requiring treatment 6\. The patient who has severe thromboembolism, including myocardial infarction, cerebral infarction, and cardiovascular complications. 7\. The patient who has uncontrollable diabetes mellitus and metabolic disease 8\. The patient who has other malignancy requiring anticancer treatment 9\. Pregnancy or nursing. 10\. At the time of enrollment as judged by the enrolling investigator would interfere with the subjects ability to comply with the study requirements

Outcomes

Primary Outcomes

Not specified

Similar Trials